Heron Therapeutics | HRTX - Interest Expense On Debt


Heron Therapeutics reported $600K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 3.64M 775K Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Eisai JPY 1.96B 409M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 18.84M 1.24M Jun/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.62M 77K Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Veracyte USD 2K 1000 Dec/2023
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025